Long	O
-	O
range	O
enhancer	O
activity	O
determines	O
Myc	O
sensitivity	O
to	O
Notch	O
inhibitors	O
in	O
T	O
cell	O
leukemia	O
.	O


Notch	O
is	O
needed	O
for	O
T	O
-	O
cell	O
development	O
and	O
is	O
a	O
common	O
oncogenic	O
driver	O
in	O
T	O
-	O
cell	O
acute	O
lymphoblastic	O
leukemia	O
.	O


The	O
protooncogene	O
c	O
-	O
Myc	O
(	O
Myc	O
)	O
is	O
a	O
critical	O
target	O
of	O
Notch	O
in	O
normal	O
and	O
malignant	O
pre	O
-	O
T	O
cells	O
,	O
but	O
how	O
Notch	O
regulates	O
Myc	O
is	O
unknown	O
.	O


Here	O
,	O
we	O
identify	O
a	O
distal	B-ENHANCER
enhancer	I-ENHANCER
located	I-ENHANCER
>	I-ENHANCER
1	I-ENHANCER
Mb	I-ENHANCER
3	I-ENHANCER
'	I-ENHANCER
of	I-ENHANCER
human	I-ENHANCER
and	I-ENHANCER
murine	I-ENHANCER
Myc	E-ENHANCER
that	O
binds	O
Notch	O
transcription	O
complexes	O
and	O
physically	O
interacts	O
with	O
the	O
Myc	O
proximal	O
promoter	O
.	O


The	O
Notch1	O
binding	O
element	O
in	O
this	O
region	O
activates	O
reporter	O
genes	O
in	O
a	O
Notch	O
-	O
dependent	O
,	O
cell	O
-	O
context	O
-	O
specific	O
fashion	O
that	O
requires	O
a	O
conserved	O
Notch	O
complex	O
binding	O
site	O
.	O


Acute	O
changes	O
in	O
Notch	O
activation	O
produce	O
rapid	O
changes	O
in	O
H3K27	O
acetylation	O
across	O
the	O
entire	O
enhancer	B-ENHANCER
(	I-ENHANCER
a	I-ENHANCER
region	I-ENHANCER
spanning	I-ENHANCER
>	I-ENHANCER
600	I-ENHANCER
kb	I-ENHANCER
)	E-ENHANCER
that	O
correlate	O
with	O
Myc	O
expression	O
.	O


This	O
broad	O
Notch	O
-	O
influenced	O
region	O
comprises	O
an	O
enhancer	B-ENHANCER
region	E-ENHANCER
containing	O
multiple	O
domains	O
,	O
recognizable	O
as	O
discrete	O
H3K27	O
acetylation	O
peaks	O
.	O


Leukemia	O
cells	O
selected	O
for	O
resistance	O
to	O
Notch	O
inhibitors	O
express	O
Myc	O
despite	O
epigenetic	O
silencing	O
of	O
enhancer	B-ENHANCER
domains	E-ENHANCER
near	O
the	O
Notch	O
transcription	O
complex	O
binding	O
sites	O
.	O


Notch	O
-	O
independent	O
expression	O
of	O
Myc	O
in	O
resistant	O
cells	O
is	O
highly	O
sensitive	O
to	O
inhibitors	O
of	O
bromodomain	O
containing	O
4	O
(	O
Brd4	O
)	O
,	O
a	O
change	O
in	O
drug	O
sensitivity	O
that	O
is	O
accompanied	O
by	O
preferential	O
association	O
of	O
the	O
Myc	O
promoter	O
with	O
more	O
3	B-ENHANCER
'	I-ENHANCER
enhancer	I-ENHANCER
domains	E-ENHANCER
that	O
are	O
strongly	O
dependent	O
on	O
Brd4	O
for	O
function	O
.	O


These	O
findings	O
indicate	O
that	O
altered	O
long	O
-	O
range	O
enhancer	O
activity	O
can	O
mediate	O
resistance	O
to	O
targeted	O
therapies	O
and	O
provide	O
a	O
mechanistic	O
rationale	O
for	O
combined	O
targeting	O
of	O
Notch	O
and	O
Brd4	O
in	O
leukemia	O
.	O
